Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Efinopegdutide (JNJ-64565111) in Type 2 Diabetes
NCT03235219Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Primary completion
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efinopegdutide in type 2 diabetes mellitus (T2DM) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. Started Aug 2017; status: completed.
02
Drugs
efinopegdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03235219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235219.